Comparative Pharmacology
Head-to-head clinical analysis: ALDORIL 25 versus TIMOLIDE 10 25.
Peer-Reviewed Evidence
Head-to-head clinical analysis: ALDORIL 25 versus TIMOLIDE 10 25.
ALDORIL 25 vs TIMOLIDE 10-25
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Combination of methyldopa, a centrally acting alpha-2 adrenergic agonist that reduces sympathetic outflow, and hydrochlorothiazide, a thiazide diuretic that inhibits sodium reabsorption in the distal convoluted tubule, reducing plasma volume.
Timolol is a non-selective beta-adrenergic receptor antagonist that blocks beta-1 and beta-2 receptors, reducing heart rate, myocardial contractility, and blood pressure. Hydrochlorothiazide is a thiazide diuretic that inhibits the sodium-chloride symporter in the distal convoluted tubule, increasing excretion of sodium and water, reducing plasma volume and blood pressure.
Oral: 1 tablet (hydrochlorothiazide 25 mg/methyldopa 250 mg) twice daily; increase as needed to max 2 tablets twice daily.
One tablet (timolol 10 mg / hydrochlorothiazide 25 mg) orally once daily. May be increased to two tablets once daily if needed.
None Documented
None Documented
7-16 hours (terminal). In renal impairment, half-life may exceed 24 hours, requiring dose adjustment.
The terminal elimination half-life of timolol is approximately 4 hours in patients with normal renal function, but may be prolonged to 12-20 hours in patients with renal impairment or hepatic dysfunction. The half-life of hydrochlorothiazide is 6-15 hours.
Renal: ~85% unchanged. Biliary/fecal: ~15% as metabolites.
Timolol is primarily eliminated by renal excretion of unchanged drug and metabolites. Approximately 20% of a dose is excreted unchanged in urine, with the remainder as metabolites (mostly inactive). Fecal elimination accounts for less than 5%.
Category C
Category C
Antihypertensive Combination
Antihypertensive Combination